Cetero Research, a US company offering clinical pharmacology, bioanalytical and speciality Phase II-IV trial services, has added a 100-bed Phase I facility to its site in San Antonio, Texas.

The new purpose-built facility is designed to run clinical pharmacology studies in healthy, diabetic and obese participants. It consolidates into a single four-story building existing operations already well known for conducting first-in-human, proof-of-concept studies and taking part in diabetes and obesity trials as a multicentre site, explained Cary, North Carolina-based Cetero.

The site has been running clinical studies for 25 years, the company added. One notable addition is increased capacity to perform euglycaemic and insulin-clamp studies, noted Dr Sherwyn Schwartz, chief executive officer of the San Antonio facility. “These specialised studies are ideal for establishing proof-of-concept for novel compounds, or even comparing compounds to show superiority or equivalence,” he said.

The facility is located on the Christus Santa Rosa Medical Campus, adjacent to one of the largest endocrinology practices in the US, which sees more than 6,500 patients per month. As well as a large database of normal healthy participants, Type I and Type II diabetics and obese patients, Cetero has access to patients with hypogonadism, neuropathy, osteoporosis and erectile dysfunction, it pointed out.